v3.26.1
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
clinicalTrial
Jun. 30, 2025
USD ($)
Accounting Policies [Abstract]        
Royalty expense | $ $ 7,061 $ 13,635 $ 31,877 $ 26,060
Number of phase 3 clinical trials in process | clinicalTrial     3